Tryptophan–kynurenine ratio as a biomarker of bladder cancer
Objectives To investigate plasma and urinary kynurenine (KYN)–tryptophan (TRP) ratios in bladder cancer, expression of indoleamine 2,3‐dioxygenase 1 (IDO1) in relation to tryptophan 2,3‐dioxygenase (TDO2) in bladder tumour, and the correlation of KYN–TRP ratio with bladder tumour burden. Methods Met...
Saved in:
Published in | BJU international Vol. 127; no. 4; pp. 445 - 453 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley Subscription Services, Inc
01.04.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objectives
To investigate plasma and urinary kynurenine (KYN)–tryptophan (TRP) ratios in bladder cancer, expression of indoleamine 2,3‐dioxygenase 1 (IDO1) in relation to tryptophan 2,3‐dioxygenase (TDO2) in bladder tumour, and the correlation of KYN–TRP ratio with bladder tumour burden.
Methods
Metabotyping of the TRP–KYN metabolic axis was performed via a clinical case–control study. Expression of IDO1 and TDO2 was measured in human biopsied tissues. Correlational experiments between KYN–TRP ratio and bladder tumour were performed using a murine orthotopic prostate‐specific antigen (PSA)‐secreting MB49 bladder cancer model.
Results
We established for the first time that plasma TRP level was significantly decreased, while both plasma and urinary KYN–TRP ratios were significantly higher in bladder cancer patients, and expression level of IDO1 but not TDO2 was increased in human bladder tumour. We reported the positive correlation between IDO1 expression, KYN–TRP ratio, normalized PSA to creatinine, and bladder tumour burden in the murine model.
Conclusion
Kynurenine–tryptophan ratio is a promising surveillance biomarker for bladder cancer, but would require further validation before clinical translation. |
---|---|
AbstractList | OBJECTIVESTo investigate plasma and urinary kynurenine (KYN)-tryptophan (TRP) ratios in bladder cancer, expression of indoleamine 2,3-dioxygenase 1 (IDO1) in relation to tryptophan 2,3-dioxygenase (TDO2) in bladder tumour, and the correlation of KYN-TRP ratio with bladder tumour burden. METHODSMetabotyping of the TRP-KYN metabolic axis was performed via a clinical case-control study. Expression of IDO1 and TDO2 was measured in human biopsied tissues. Correlational experiments between KYN-TRP ratio and bladder tumour were performed using a murine orthotopic prostate-specific antigen (PSA)-secreting MB49 bladder cancer model. RESULTSWe established for the first time that plasma TRP level was significantly decreased, while both plasma and urinary KYN-TRP ratios were significantly higher in bladder cancer patients, and expression level of IDO1 but not TDO2 was increased in human bladder tumour. We reported the positive correlation between IDO1 expression, KYN-TRP ratio, normalized PSA to creatinine, and bladder tumour burden in the murine model. CONCLUSIONKynurenine-tryptophan ratio is a promising surveillance biomarker for bladder cancer, but would require further validation before clinical translation. Objectives To investigate plasma and urinary kynurenine (KYN)–tryptophan (TRP) ratios in bladder cancer, expression of indoleamine 2,3‐dioxygenase 1 (IDO1) in relation to tryptophan 2,3‐dioxygenase (TDO2) in bladder tumour, and the correlation of KYN–TRP ratio with bladder tumour burden. Methods Metabotyping of the TRP–KYN metabolic axis was performed via a clinical case–control study. Expression of IDO1 and TDO2 was measured in human biopsied tissues. Correlational experiments between KYN–TRP ratio and bladder tumour were performed using a murine orthotopic prostate‐specific antigen (PSA)‐secreting MB49 bladder cancer model. Results We established for the first time that plasma TRP level was significantly decreased, while both plasma and urinary KYN–TRP ratios were significantly higher in bladder cancer patients, and expression level of IDO1 but not TDO2 was increased in human bladder tumour. We reported the positive correlation between IDO1 expression, KYN–TRP ratio, normalized PSA to creatinine, and bladder tumour burden in the murine model. Conclusion Kynurenine–tryptophan ratio is a promising surveillance biomarker for bladder cancer, but would require further validation before clinical translation. To investigate plasma and urinary kynurenine (KYN)-tryptophan (TRP) ratios in bladder cancer, expression of indoleamine 2,3-dioxygenase 1 (IDO1) in relation to tryptophan 2,3-dioxygenase (TDO2) in bladder tumour, and the correlation of KYN-TRP ratio with bladder tumour burden. Metabotyping of the TRP-KYN metabolic axis was performed via a clinical case-control study. Expression of IDO1 and TDO2 was measured in human biopsied tissues. Correlational experiments between KYN-TRP ratio and bladder tumour were performed using a murine orthotopic prostate-specific antigen (PSA)-secreting MB49 bladder cancer model. We established for the first time that plasma TRP level was significantly decreased, while both plasma and urinary KYN-TRP ratios were significantly higher in bladder cancer patients, and expression level of IDO1 but not TDO2 was increased in human bladder tumour. We reported the positive correlation between IDO1 expression, KYN-TRP ratio, normalized PSA to creatinine, and bladder tumour burden in the murine model. Kynurenine-tryptophan ratio is a promising surveillance biomarker for bladder cancer, but would require further validation before clinical translation. |
Author | Tham, Sin Mun Chia, Jun Yang Goh, Benjamin Yen Seow Chiong, Edmund Lim, Yi Xin Mahendran, Ratha Esuvaranathan, Kesavan Mallari, Jeane Zepeda Choo, Shoa Nian Chan, Eric Chun Yong Wu, Qing Hui Periaswami, Revathi Tay, Melissa Hui Wen Chionh, Billy Jianhao Raman, Lata Kioh, Dorinda Yan Qin Tsang, Woon Chau Lee, Sze Han Thamboo, Thomas Paulraj Chen, Kelven Weijing |
Author_xml | – sequence: 1 givenname: Sze Han surname: Lee fullname: Lee, Sze Han organization: National University of Singapore – sequence: 2 givenname: Ratha surname: Mahendran fullname: Mahendran, Ratha organization: National University of Singapore – sequence: 3 givenname: Sin Mun surname: Tham fullname: Tham, Sin Mun organization: National University of Singapore – sequence: 4 givenname: Thomas Paulraj surname: Thamboo fullname: Thamboo, Thomas Paulraj organization: National University Health System – sequence: 5 givenname: Billy Jianhao surname: Chionh fullname: Chionh, Billy Jianhao organization: National University of Singapore – sequence: 6 givenname: Yi Xin surname: Lim fullname: Lim, Yi Xin organization: National University of Singapore – sequence: 7 givenname: Woon Chau surname: Tsang fullname: Tsang, Woon Chau organization: National University Health System – sequence: 8 givenname: Qing Hui surname: Wu fullname: Wu, Qing Hui organization: National University Health System – sequence: 9 givenname: Jun Yang surname: Chia fullname: Chia, Jun Yang organization: National University Health System – sequence: 10 givenname: Melissa Hui Wen surname: Tay fullname: Tay, Melissa Hui Wen organization: National University Health System – sequence: 11 givenname: Benjamin Yen Seow surname: Goh fullname: Goh, Benjamin Yen Seow organization: National University Health System – sequence: 12 givenname: Kelven Weijing surname: Chen fullname: Chen, Kelven Weijing organization: National University Health System – sequence: 13 givenname: Jeane Zepeda surname: Mallari fullname: Mallari, Jeane Zepeda organization: National University Health System – sequence: 14 givenname: Revathi surname: Periaswami fullname: Periaswami, Revathi organization: National University of Singapore – sequence: 15 givenname: Lata surname: Raman fullname: Raman, Lata organization: National University of Singapore – sequence: 16 givenname: Shoa Nian surname: Choo fullname: Choo, Shoa Nian organization: National University Health System – sequence: 17 givenname: Dorinda Yan Qin surname: Kioh fullname: Kioh, Dorinda Yan Qin organization: National University of Singapore – sequence: 18 givenname: Edmund surname: Chiong fullname: Chiong, Edmund organization: National University Health System – sequence: 19 givenname: Kesavan surname: Esuvaranathan fullname: Esuvaranathan, Kesavan organization: National University Health System – sequence: 20 givenname: Eric Chun Yong orcidid: 0000-0001-6107-9072 surname: Chan fullname: Chan, Eric Chun Yong email: phaccye@nus.edu.sg organization: National University of Singapore |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32794357$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kMlKA0EQhhuJmEUPvoAMeNFDtNdZLoIGVwJeEvDWdM9U48RJd-zOILn5Dr6hT2JrEg-Cdami-Pio-vuoY50FhA4JPiOxzvWsPSOCYrGDeoSnfMgJfupsZ1ykXdQPYYZxXKRiD3UZzQrORNZDFxO_Wizd4lnZz_ePl5VtPdjaQuLVsnaJColKdO3myr-AT5xJdKOqKo6lsiX4fbRrVBPgYNMHaHpzPRndDcePt_ejy_GwZIKJYa40zwzHORWgMGFaUEoMhawyYIQhtCpSkWrBeKkELUpFBU9VAZprQ8BQNkAna-_Cu9cWwlLO61BC0ygLrg2ScsZ5TnJOInr8B5251tt4naSCEJwXOcsidbqmSu9C8GDkwtfxy5UkWH6HKmOo8ifUyB5tjK2eQ_VLblOMwPkaeKsbWP1vklcP07XyC7l5gio |
CitedBy_id | crossref_primary_10_2147_IJN_S354590 crossref_primary_10_3748_wjg_v26_i45_7173 crossref_primary_10_3389_fimmu_2023_1283792 crossref_primary_10_1016_j_bcp_2024_116172 crossref_primary_10_1039_D4AN00418C crossref_primary_10_2174_1871530322666220104103905 crossref_primary_10_1007_s00726_021_03113_5 crossref_primary_10_3389_fonc_2023_1116016 crossref_primary_10_1038_s41598_023_36874_y crossref_primary_10_3389_fonc_2024_1331215 crossref_primary_10_3390_ijms22094403 crossref_primary_10_1016_j_canlet_2023_216076 crossref_primary_10_1186_s12885_021_08855_9 crossref_primary_10_1186_s40170_023_00324_0 crossref_primary_10_3390_metabo12020154 crossref_primary_10_1016_j_ajur_2022_11_005 crossref_primary_10_3389_fonc_2022_852718 crossref_primary_10_20517_mrr_2023_47 |
Cites_doi | 10.1158/0008-5472.CAN-17-2285 10.1007/s40273-014-0194-2 10.1200/JCO.2019.37.7_suppl.358 10.1200/JCO.2019.37.7_suppl.TPS493 10.1111/j.1464-410X.2008.08323.x 10.7326/M15-0997 10.1038/nature10491 10.1111/bju.13760 10.1016/j.jchromb.2017.04.010 10.1158/1078-0432.CCR-18-2882 10.1016/j.tranon.2018.11.012 10.3322/caac.20073 10.1158/1078-0432.CCR-04-0605 10.1111/j.1464-410X.2008.07966.x 10.1016/S0140-6736(16)30512-8 10.1126/science.1260419 10.1016/j.eururo.2009.06.028 10.1200/JCO.2001.19.3.666 10.1073/pnas.1113873109 10.1016/j.juro.2016.06.049 10.1016/j.eururo.2012.09.057 10.1021/pr901173v 10.1016/j.clinbiochem.2018.04.014 10.4137/IJTR.S38189 10.4049/jimmunol.1000815 10.1177/1178646917694600 10.1089/met.2017.0097 |
ContentType | Journal Article |
Copyright | 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd. BJUI © 2021 BJU International |
Copyright_xml | – notice: 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd – notice: 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd. – notice: BJUI © 2021 BJU International |
DBID | NPM AAYXX CITATION 7QP 7X8 |
DOI | 10.1111/bju.15205 |
DatabaseName | PubMed CrossRef Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Calcium & Calcified Tissue Abstracts PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1464-410X |
EndPage | 453 |
ExternalDocumentID | 10_1111_bju_15205 32794357 BJU15205 |
Genre | article Journal Article |
GrantInformation_xml | – fundername: National University Health System (NUHS) Innovation Grant funderid: NUHSRO/2018/041/Innov/03 – fundername: NUHS Global Collaboration Centre Grant funderid: NUHSRO/2015/065/GCC/02 – fundername: National University Health System (NUHS) Innovation Grant grantid: NUHSRO/2018/041/Innov/03 – fundername: NUHS Global Collaboration Centre Grant grantid: NUHSRO/2015/065/GCC/02 |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT NPM AAMNL AAYXX CITATION 7QP 7X8 |
ID | FETCH-LOGICAL-c3535-8ab47f40825ea013b5221f2e7dfef5f12d9656b534ca529ca2546a9eb4bf1ef23 |
IEDL.DBID | DR2 |
ISSN | 1464-4096 |
IngestDate | Wed Dec 04 06:22:30 EST 2024 Tue Nov 19 04:44:16 EST 2024 Fri Dec 06 01:05:45 EST 2024 Sat Sep 28 08:23:23 EDT 2024 Sat Aug 24 01:02:22 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | uroonc blcsm bladder cancer kynurenine utuc surveillance BladderCancer biomarker tryptophan |
Language | English |
License | 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3535-8ab47f40825ea013b5221f2e7dfef5f12d9656b534ca529ca2546a9eb4bf1ef23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-6107-9072 |
PMID | 32794357 |
PQID | 2511089837 |
PQPubID | 1026371 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2434481841 proquest_journals_2511089837 crossref_primary_10_1111_bju_15205 pubmed_primary_32794357 wiley_primary_10_1111_bju_15205_BJU15205 |
PublicationCentury | 2000 |
PublicationDate | April 2021 2021-Apr 2021-04-00 20210401 |
PublicationDateYYYYMMDD | 2021-04-01 |
PublicationDate_xml | – month: 04 year: 2021 text: April 2021 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Edgecliff |
PublicationTitle | BJU international |
PublicationTitleAlternate | BJU Int |
PublicationYear | 2021 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2017; 119 2015; 163 2011; 478 1973; 33 2015; 347 2019; 12 2019; 37 2013; 63 2016; 388 2008; 102 2015; 8 2012; 109 2010; 60 2009; 56 2004; 10 2017; 1054 2017; 77 2017; 10 2019; 25 2001; 19 2015; 2017 2018; 56 2018; 16 2016; 196 2009; 104 2016; 9 2014; 32 2010; 9 2011; 187 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 Gailani S (e_1_2_7_15_1) 1973; 33 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_2_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_28_1 (NICE) NI of H and CE (e_1_2_7_12_1) 2015; 2017 e_1_2_7_29_1 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 Yang C (e_1_2_7_18_1) 2015; 8 e_1_2_7_24_1 e_1_2_7_23_1 e_1_2_7_22_1 e_1_2_7_21_1 e_1_2_7_20_1 |
References_xml | – volume: 8 start-page: 1768 year: 2015 end-page: 75 article-title: Expression and function analysis of indoleamine 2 and 3‐dioxygenase in bladder urothelial carcinoma publication-title: Int J Clin Exp Pathol – volume: 16 start-page: 135 year: 2018 end-page: 42 article-title: Dysregulation of tryptophan catabolism in metabolic syndrome publication-title: Metab Synd Relat Disord – volume: 388 start-page: 2796 year: 2016 end-page: 810 article-title: Bladder cancer publication-title: Lancet – volume: 56 start-page: 83 year: 2018 end-page: 8 article-title: Mass spectrometric measurement of urinary kynurenine‐to‐tryptophan ratio in children with and without urinary tract infection publication-title: Clin Biochem – volume: 10 start-page: 6977 year: 2004 end-page: 84 article-title: Monitoring the response of orthotopic bladder tumors to granulocyte macrophage colony‐stimulating factor therapy using the prostate‐specific antigen gene as a reporter publication-title: Clin Cancer Res – volume: 37 start-page: 358 issue: 7_suppl year: 2019 article-title: BMS‐986205, an indoleamine 2, 3‐dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC) publication-title: J Clin Oncol – volume: 32 start-page: 1093 year: 2014 end-page: 104 article-title: The health economics of bladder cancer: an updated review of the published literature publication-title: Pharmacoeconomics – volume: 9 start-page: 31 year: 2016 end-page: 49 article-title: Assessment of the human kynurenine pathway: comparisons and clinical implications of ethnic and gender differences in plasma tryptophan, kynurenine metabolites, and enzyme expressions at baseline and after acute tryptophan loading and depletion publication-title: Int J Tryptophan Res – volume: 10 start-page: 117864691769460 year: 2017 article-title: Tryptophan metabolism in patients with chronic kidney disease secondary to type 2 diabetes: Relationship to inflammatory markers publication-title: Int J Tryptophan Res – volume: 19 start-page: 666 year: 2001 end-page: 75 article-title: Radical cystectomy in the treatment of invasive bladder cancer: long‐term results in 1,054 patients publication-title: J Clin Oncol – volume: 37 start-page: TPS493 year: 2019 article-title: A phase II, randomized study of nivolumab (nivo) or nivo plus BMS‐986205 with or without intravesical Bacillus Calmette‐Guerin (BCG) in BCG‐unresponsive, high‐risk, non‐muscle invasive bladder cancer (NMIBC): CheckMate 9UT publication-title: J Clin Oncol – volume: 56 start-page: 430 year: 2009 end-page: 42 article-title: Recurrence and Progression of disease in non‐muscle‐invasive bladder cancer: from epidemiology to treatment strategy publication-title: Eur Urol – volume: 163 start-page: 922 year: 2015 article-title: Urinary biomarkers for diagnosis of bladder cancer publication-title: Ann Intern Med – volume: 187 start-page: 1617 year: 2011 end-page: 25 article-title: IDO induces expression of a novel tryptophan transporter in mouse and human tumor cells publication-title: J Immunol – volume: 104 start-page: 41 year: 2009 end-page: 7 article-title: Non‐muscle‐invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost‐effective alternative? publication-title: BJU Int – volume: 196 start-page: 1021 year: 2016 end-page: 9 article-title: Diagnosis and treatment of non‐muscle invasive bladder cancer: AUA/SUO guideline publication-title: J Urol – volume: 77 start-page: 6795 year: 2017 end-page: 811 article-title: Discovery of IDO1 inhibitors: from bench to bedside publication-title: Cancer Res – volume: 102 start-page: 1242 year: 2008 end-page: 6 article-title: Quality control in transurethral resection of bladder tumours publication-title: BJU Int – volume: 109 start-page: 2497 year: 2012 end-page: 502 article-title: Reversal of tumoral immune resistance by inhibition of tryptophan 2,3‐dioxygenase publication-title: Proc Natl Acad Sci USA – volume: 25 start-page: 1462 year: 2019 end-page: 71 article-title: Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan–kynurenine–aryl hydrocarbon axis publication-title: Clin Cancer Res – volume: 2017 start-page: 755 year: 2015 end-page: 65 article-title: Bladder cancer: diagnosis and management of bladder cancer: © NICE (2015) Bladder cancer: diagnosis and management of bladder cancer publication-title: BJU Int – volume: 33 start-page: 1071 year: 1973 end-page: 7 article-title: Studies on tryptophan metabolism in patients with bladder cancer publication-title: Cancer Res – volume: 12 start-page: 485 year: 2019 end-page: 92 article-title: Overexpression of indoleamine 2,3‐dioxygenase 1 promotes epithelial‐mesenchymal transition by activation of the IL‐6/STAT3/PD‐L1 pathway in bladder cancer publication-title: Transl Oncol – volume: 478 start-page: 197 year: 2011 end-page: 203 article-title: An endogenous tumour‐promoting ligand of the human aryl hydrocarbon receptor publication-title: Nature – volume: 60 start-page: 277 year: 2010 end-page: 300 article-title: Cancer statistics, 2010 publication-title: CA Cancer J Clin – volume: 347 start-page: 1260419 year: 2015 article-title: Tissue‐based map of the human proteome publication-title: Science – volume: 1054 start-page: 36 year: 2017 end-page: 43 article-title: Simultaneous determination of tryptophan and 8 metabolites in human plasma by liquid chromatography/tandem mass spectrometry publication-title: J Chromatogr B Anal Technol Biomed Life Sci – volume: 63 start-page: 4 year: 2013 end-page: 15 article-title: ICUD‐EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers publication-title: Eur Urol – volume: 119 start-page: 371 year: 2017 end-page: 80 article-title: Guideline of guidelines: non‐muscle‐invasive bladder cancer publication-title: BJU Int – volume: 9 start-page: 2988 year: 2010 end-page: 95 article-title: Noninvasive urinary metabonomic diagnosis of human bladder cancer publication-title: J Proteome Res – ident: e_1_2_7_25_1 doi: 10.1158/0008-5472.CAN-17-2285 – ident: e_1_2_7_8_1 doi: 10.1007/s40273-014-0194-2 – ident: e_1_2_7_26_1 doi: 10.1200/JCO.2019.37.7_suppl.358 – volume: 8 start-page: 1768 year: 2015 ident: e_1_2_7_18_1 article-title: Expression and function analysis of indoleamine 2 and 3‐dioxygenase in bladder urothelial carcinoma publication-title: Int J Clin Exp Pathol contributor: fullname: Yang C – ident: e_1_2_7_27_1 doi: 10.1200/JCO.2019.37.7_suppl.TPS493 – ident: e_1_2_7_9_1 doi: 10.1111/j.1464-410X.2008.08323.x – ident: e_1_2_7_13_1 doi: 10.7326/M15-0997 – ident: e_1_2_7_17_1 doi: 10.1038/nature10491 – ident: e_1_2_7_10_1 doi: 10.1111/bju.13760 – ident: e_1_2_7_21_1 doi: 10.1016/j.jchromb.2017.04.010 – ident: e_1_2_7_28_1 doi: 10.1158/1078-0432.CCR-18-2882 – ident: e_1_2_7_19_1 doi: 10.1016/j.tranon.2018.11.012 – ident: e_1_2_7_3_1 doi: 10.3322/caac.20073 – ident: e_1_2_7_20_1 doi: 10.1158/1078-0432.CCR-04-0605 – ident: e_1_2_7_5_1 doi: 10.1111/j.1464-410X.2008.07966.x – ident: e_1_2_7_2_1 doi: 10.1016/S0140-6736(16)30512-8 – ident: e_1_2_7_22_1 doi: 10.1126/science.1260419 – ident: e_1_2_7_4_1 doi: 10.1016/j.eururo.2009.06.028 – ident: e_1_2_7_6_1 doi: 10.1200/JCO.2001.19.3.666 – ident: e_1_2_7_23_1 doi: 10.1073/pnas.1113873109 – ident: e_1_2_7_7_1 doi: 10.1016/j.juro.2016.06.049 – volume: 2017 start-page: 755 year: 2015 ident: e_1_2_7_12_1 article-title: Bladder cancer: diagnosis and management of bladder cancer: © NICE (2015) Bladder cancer: diagnosis and management of bladder cancer publication-title: BJU Int contributor: fullname: (NICE) NI of H and CE – ident: e_1_2_7_11_1 doi: 10.1016/j.eururo.2012.09.057 – volume: 33 start-page: 1071 year: 1973 ident: e_1_2_7_15_1 article-title: Studies on tryptophan metabolism in patients with bladder cancer publication-title: Cancer Res contributor: fullname: Gailani S – ident: e_1_2_7_14_1 doi: 10.1021/pr901173v – ident: e_1_2_7_31_1 doi: 10.1016/j.clinbiochem.2018.04.014 – ident: e_1_2_7_29_1 doi: 10.4137/IJTR.S38189 – ident: e_1_2_7_24_1 doi: 10.4049/jimmunol.1000815 – ident: e_1_2_7_16_1 doi: 10.1177/1178646917694600 – ident: e_1_2_7_30_1 doi: 10.1089/met.2017.0097 |
SSID | ssj0014665 |
Score | 2.502656 |
Snippet | Objectives
To investigate plasma and urinary kynurenine (KYN)–tryptophan (TRP) ratios in bladder cancer, expression of indoleamine 2,3‐dioxygenase 1 (IDO1) in... To investigate plasma and urinary kynurenine (KYN)-tryptophan (TRP) ratios in bladder cancer, expression of indoleamine 2,3-dioxygenase 1 (IDO1) in relation to... ObjectivesTo investigate plasma and urinary kynurenine (KYN)–tryptophan (TRP) ratios in bladder cancer, expression of indoleamine 2,3‐dioxygenase 1 (IDO1) in... OBJECTIVESTo investigate plasma and urinary kynurenine (KYN)-tryptophan (TRP) ratios in bladder cancer, expression of indoleamine 2,3-dioxygenase 1 (IDO1) in... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 445 |
SubjectTerms | Animal models biomarker Biomarkers Bladder cancer BladderCancer blcsm Cancer Creatinine Dioxygenase kynurenine Prostate surveillance Tryptophan Tumors uroonc utuc |
Title | Tryptophan–kynurenine ratio as a biomarker of bladder cancer |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbju.15205 https://www.ncbi.nlm.nih.gov/pubmed/32794357 https://www.proquest.com/docview/2511089837 https://search.proquest.com/docview/2434481841 |
Volume | 127 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NatwwEB5CAqGXtkn_3G6CUnroxcG2pPWKQGG3ybIEkkPIQg4FI9nSoSne4F0ftqe-Q98wT5IZ-YcmJRByskESsjUz0jfS6BuAL0O0mcQKFSZFykOhchlqI1WoRSSsjRwuKbTfcXY-nM3F6ZW82oCj7i5Mww_Rb7iRZfj5mgxcm-U_Rm5-1pS8x_OXxjylcL7ji546CicAn0YSnwJ9JDVsWYUoiqdveX8t-g9g3serfsGZvoIf3ac2cSbXh_XKHOa_H7A4PvNfXsPLFoiycaM5O7Bhy13YPmuP2t_At8tqfUOsA7q8_fP3ek0XikssYV5lmF4yzejuPoX3VGzhmPlFk1jFctKj6i3MpyeX32dhm2whzLnkMhxpI1JH6ael1YgLDQKz2CU2LZx1EmVWKIR-RnKRa5moXBORvlbWCONi6xL-DjbLRWk_ACsQsEdS28KpkZCU3yeKDXcmyVNKau0C-NwNe3bTcGpknS-CI5H5kQhg0Akka81qmZE_FI0UOtUBHPTFaBB0yqFLu6ixjuDocqLjGgfwvhFk3wtPiA9PYuuvXhyPd59NTuf-5ePTq36CFwlFvPi4ngFsrqra7iFkWZl92BpPjifTfa-jdyV250w |
link.rule.ids | 314,780,784,1375,27924,27925,46294,46718 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSyQxEC5EQffic1fHZ5Q97KWlH8nMBETwyfgYD8sMeJEm6U4OjvRIO3PQk__Bf-gvsSr9QFcWxFM3JCHdqarkq6TyFcDvJtpMaLj0wrQVeVwmwlNaSE9xnxvjW1xSaL-je9Xs9Pn5tbiegL3qLkzBD1FvuJFluPmaDJw2pN9Zub4dU_YeIjCdQnMPKKDr-G9NHoVTgEskiU-OXpJslrxCFMdTN_24Gn2CmB8Rq1tyTufgpvrYItJksDse6d3k6R8ex-_-zTzMlliUHRTKswATJluE6W552r4E-7388Z6IB1T2-vwyeKQ7xRmWMKc1TD0wxej6PkX45Gxomb6jeSxnCalS_hP6pye9o45X5lvwkkhEwmsrzVuWMlALoxAaasRmgQ1NK7XGChRbKhH9aRHxRIlQJoq49JU0mmsbGBtGv2AyG2ZmBViKmN0XyqRWtrmgFD9-oCOrw6RFea1tA3aqcY_vC1qNuHJHcCRiNxINWK8kEpeW9RCTS-S3JfrVDdiui9Em6KBDZWY4xjo8Qq8TfdegAcuFJOteopAo8QS2_uPk8f_u48PzvntZ_XrVLZjp9LqX8eXZ1cUa_AgpAMaF-azD5Cgfmw1EMCO96RT1DWLu6fs |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NahsxEB5CCqGXtkmb1onTqCGHXDastZJtESi0TYzr_FCKDT4EFmlXOtRlbdb2wT31HfKGeZLMaH9oEgKhp12QhHY1M9I30ugbgMM22gy3QgU87USBUIkMtJEq0CIU1oYOlxTa77i8avdHYjCW4zU4qe7CFPwQ9YYbWYafr8nAZ6n7x8jNryUl7yH-0heizRUR55_-rLmjcAbweSTxKdBJUu2SVojCeOqm9xejRwjzPmD1K07vNVxX31oEmkyOlwtznPx5QOP4nz_zBl6VSJR9KVRnE9ZstgUbl-VZ-1v4PMxXM6Id0Nnt35vJim4UZ1jCvM4wPWea0eV9iu_J2dQx85tmsZwlpEj5Oxj1zobf-kGZbSFIIhnJoKuN6DjKPy2tRmBoEJm1HLed1FknUWipQuxnZCQSLblKNDHpa2WNMK5lHY-2YT2bZvYDsBQReyi1TZ3qCkkJfsKWiZzhSYeyWrsGHFTDHs8KUo24ckZwJGI_Eg1oVgKJS7uax-QQhV2FXnUDPtXFaBF0zKEzO11iHRGhz4mea6sB7wtB1r1EnAjxJLY-8uJ4uvv462DkX3aeX3UfNn6c9uKL71fnu_CSU_SLj_FpwvoiX9o9hC8L89Gr6R26Meiq |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tryptophan-kynurenine+ratio+as+a+biomarker+of+bladder+cancer&rft.jtitle=BJU+international&rft.au=Lee%2C+Sze+Han&rft.au=Mahendran%2C+Ratha&rft.au=Tham%2C+Sin+Mun&rft.au=Thamboo%2C+Thomas+Paulraj&rft.date=2021-04-01&rft.eissn=1464-410X&rft.volume=127&rft.issue=4&rft.spage=445&rft.epage=453&rft_id=info:doi/10.1111%2Fbju.15205&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |